A phase II study of lenvatinib a multi-targeted tyrosine kinase inhibitor combined with pembrolizumab (PD-1 inhibitor) for the treatment of metastatic gastroesophageal cancer patients who have progressed on first or subsequent line therapies

Brief description of study

If you have been diagnosed with gastroesophageal, stomach, or gastroesophageal junction (GEJ) cancers, you may qualify for this clinical trial. The goal of this phase II study is to determine whether combination therapy of lenvatinib ( LENVIMA®) with pembrolizumab ( KEYTRUDA®) is safe and effective in treating metastatic gastroesophageal cancer that has progressed on first or subsequent line{s) therapies. This study will also determine what effects lenvatinib and pembrolizumab has on you and your disease.

Clinical Study Identifier: s17-00626

ClinicalTrials.gov Identifier: NCT03321630

Principal Investigator: Paul E. Oberstein.

Other Investigators: Daniel J Becker, Shun Yu, Elaine Shum, Jennifer Chuy, Nina Beri, Jennifer Wu.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies